Cue Biopharma (CUE) Expected to Demonstrate Tumor Shinkage Monday AMC - BTIG

August 31, 2020 6:08 AM EDT
Get Alerts CUE Hot Sheet
Price: $14.78 -0.87%

Rating Summary:
    7 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 17 | Down: 5 | New: 35
Trade Now! 
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

BTIG analyst Thomas Shrader reiterated a Buy rating and $33.00 price target on Cue Biopharma (NASDAQ: CUE) ahead of reporting delayed results on Monday night (10-Q out already)
that will include additional scan data for as many patients as possible for a significant data readout. It is believed that the company wants to show a true response of either 30% shrinkage and confirmed or at least some tumors with 15% to 20% shrinkage.

The analyst stated "Based on the approach of targeting viral antigens (true non-self targets) and the animal data, we are optimistic albeit realistic that these are very late-stage patients and the CUE-101 requires the patients to mount a meaningful anti-tumor immune response. The goal of this P1 trial is to define a monotherapy ORR greater than ~15% to 20% or two standard deviations above the expected SOC for these patients (pretty close to 0%). Barring that level of efficacy, the developmental goal for CUE-101 will likely become the characterization of dose dependent PD effects for monotherapy that support a pivotal trial in combination with a PD1 inhibitor. For reference, the ICOS-agonist mAb GSK3359609 was recently into P3 trials after showing a monotherapy ORR of 6% in a similar patient population (INDUCE-1 study, ORR = 24% was shown for Keytruda combination in CPI-naive patients)".

For an analyst ratings summary and ratings history on Cue Biopharma click here. For more ratings news on Cue Biopharma click here.

Shares of Cue Biopharma closed at $17.73 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Related Entities